Brief Summary
This is a single arm, multi-center, prospective study that will evaluate the safety and efficacy of the Omnipod 5 Automated Insulin Delivery System in adults with type 2 diabetes requiring insulin therapy.
Brief Title
OP5-005 Using Omnipod 5 in Adults With Type 2
Detailed Description
This outpatient study consists of 2 phases.
Phase 1 is a 14-day period to collect baseline glucose and insulin data. Participants will manage their diabetes as an outpatient per their usual routine. During this time participants will wear a blinded continuous glucose monitor to collect baseline glycemic information.
Phase 2 is a 13 week treatment period during which participants will use the Omnipod 5 System consisting of the Omnipod 5 pod, Omnipod 5 app as well as a Dexcom G6 continuous glucose monitor. Participants will do in-clinic or virtual visits at least monthly for a total of 8 visits. During the treatment period all participants will undergo supervised exercise and meal challenges.
Phase 1 is a 14-day period to collect baseline glucose and insulin data. Participants will manage their diabetes as an outpatient per their usual routine. During this time participants will wear a blinded continuous glucose monitor to collect baseline glycemic information.
Phase 2 is a 13 week treatment period during which participants will use the Omnipod 5 System consisting of the Omnipod 5 pod, Omnipod 5 app as well as a Dexcom G6 continuous glucose monitor. Participants will do in-clinic or virtual visits at least monthly for a total of 8 visits. During the treatment period all participants will undergo supervised exercise and meal challenges.
Completion Date
Completion Date Type
Actual
Conditions
Type2 Diabetes
Eligibility Criteria
Inclusion Criteria:
1. Age at time of consent 18-75 years
2. Diagnosed with type 2 diabetes, on current insulin regimen for at least 3 months prior to screening (i.e. Basal-bolus, basal only or pre-mix)
3. Basal bolus (long-acting insulin and rapid acting analog) or pre-mix users with A1C \<12.0% OR basal users on long or intermediate acting insulin only with A1C \> 7.0% and \< 12.0%
4. Willing to use only the following types of U-100 insulin during the study: Humalog U-100, Novolog, or Admelog
5. Participant agrees to provide their own insulin for the duration of the study
6. Stable doses over the preceding 4 weeks of other glucose-lowering medications as determined by Investigator
7. Stable doses of weight loss medications over the preceding 4 weeks and throughout the study that may affect glycemic control directly and/or indirectly, except for a dose reduction or discontinuation, as determined by Investigator
8. Willing to wear the system continuously throughout the study
9. Deemed appropriate for pump therapy per investigator's assessment considering previous history of severe hypoglycemic and hyperglycemic events, and other comorbidities
10. Investigator has confidence that the participant has the cognitive ability and can successfully operate all study devices and can adhere to the protocol
11. Able to read and understand English or Spanish
12. Willing and able to sign the Informed Consent Form (ICF)
13. If female of childbearing potential, willing and able to have pregnancy testing
Exclusion Criteria:
1. Use of an AID pump in automated mode within 3 months prior to screening
2. Any medical condition which in the opinion of the investigator, would put the participant at an unacceptable safety risk, such as untreated malignancy, unstable cardiac disease, unstable or end-stage renal disease, and/or eating disorders (i.e. anorexia/bulimia)
3. Current or known history of coronary artery disease that is not stable with medical management, including unstable angina, or angina that prevents moderate exercise despite medical management, or a history of myocardial infarction, percutaneous coronary intervention, or coronary artery bypass grafting within the 12 months prior to screening
4. Any planned surgery during the study which could be considered major in the opinion of the investigator
5. History of more than 1 severe hypoglycemic event in the 6 months prior to screening
6. History of more than 1 episode of diabetic ketoacidosis (DKA) or Hyperosmolar hyperglycemic syndrome (HHS) in the 6 months prior to screening; unrelated to an intercurrent illness; kinked, dislodged, or occluded cannula; or initial diabetes diagnosis
7. Blood disorder or dyscrasia within 3 months prior to screening, including use of hydroxyurea, which in the investigator's opinion could interfere with determination of HbA1c
8. Plans to receive blood transfusion over the course of the study
9. Has taken oral or injectable steroids within 8 weeks prior to screening or plans to take oral or injectable steroids during the study
10. Unable to tolerate adhesive tape or has any unresolved skin condition that could impact sensor or pump placement
11. Pregnant or lactating, planning to become pregnant during the study, or is a woman of childbearing potential and not on acceptable form of birth control (acceptable includes abstinence, condoms, oral/injectable contraceptives, IUD, or implant); childbearing potential means that menstruation has started, and the participant is not surgically sterile or greater than 12 months post-menopausal)
12. Participation in another clinical study using an investigational drug or device other than the Omnipod 5 in the 30 days prior to screening or intends to participate during the study period
13. Unable to follow clinical protocol for the duration of the study or is otherwise deemed unacceptable to participate in the study per the investigator's clinical judgment
14. Participant is an employee of Insulet, an Investigator or Investigator's study team, or immediate family member (spouse, biological or legal guardian, child, sibling, parent) of any of the aforementioned
1. Age at time of consent 18-75 years
2. Diagnosed with type 2 diabetes, on current insulin regimen for at least 3 months prior to screening (i.e. Basal-bolus, basal only or pre-mix)
3. Basal bolus (long-acting insulin and rapid acting analog) or pre-mix users with A1C \<12.0% OR basal users on long or intermediate acting insulin only with A1C \> 7.0% and \< 12.0%
4. Willing to use only the following types of U-100 insulin during the study: Humalog U-100, Novolog, or Admelog
5. Participant agrees to provide their own insulin for the duration of the study
6. Stable doses over the preceding 4 weeks of other glucose-lowering medications as determined by Investigator
7. Stable doses of weight loss medications over the preceding 4 weeks and throughout the study that may affect glycemic control directly and/or indirectly, except for a dose reduction or discontinuation, as determined by Investigator
8. Willing to wear the system continuously throughout the study
9. Deemed appropriate for pump therapy per investigator's assessment considering previous history of severe hypoglycemic and hyperglycemic events, and other comorbidities
10. Investigator has confidence that the participant has the cognitive ability and can successfully operate all study devices and can adhere to the protocol
11. Able to read and understand English or Spanish
12. Willing and able to sign the Informed Consent Form (ICF)
13. If female of childbearing potential, willing and able to have pregnancy testing
Exclusion Criteria:
1. Use of an AID pump in automated mode within 3 months prior to screening
2. Any medical condition which in the opinion of the investigator, would put the participant at an unacceptable safety risk, such as untreated malignancy, unstable cardiac disease, unstable or end-stage renal disease, and/or eating disorders (i.e. anorexia/bulimia)
3. Current or known history of coronary artery disease that is not stable with medical management, including unstable angina, or angina that prevents moderate exercise despite medical management, or a history of myocardial infarction, percutaneous coronary intervention, or coronary artery bypass grafting within the 12 months prior to screening
4. Any planned surgery during the study which could be considered major in the opinion of the investigator
5. History of more than 1 severe hypoglycemic event in the 6 months prior to screening
6. History of more than 1 episode of diabetic ketoacidosis (DKA) or Hyperosmolar hyperglycemic syndrome (HHS) in the 6 months prior to screening; unrelated to an intercurrent illness; kinked, dislodged, or occluded cannula; or initial diabetes diagnosis
7. Blood disorder or dyscrasia within 3 months prior to screening, including use of hydroxyurea, which in the investigator's opinion could interfere with determination of HbA1c
8. Plans to receive blood transfusion over the course of the study
9. Has taken oral or injectable steroids within 8 weeks prior to screening or plans to take oral or injectable steroids during the study
10. Unable to tolerate adhesive tape or has any unresolved skin condition that could impact sensor or pump placement
11. Pregnant or lactating, planning to become pregnant during the study, or is a woman of childbearing potential and not on acceptable form of birth control (acceptable includes abstinence, condoms, oral/injectable contraceptives, IUD, or implant); childbearing potential means that menstruation has started, and the participant is not surgically sterile or greater than 12 months post-menopausal)
12. Participation in another clinical study using an investigational drug or device other than the Omnipod 5 in the 30 days prior to screening or intends to participate during the study period
13. Unable to follow clinical protocol for the duration of the study or is otherwise deemed unacceptable to participate in the study per the investigator's clinical judgment
14. Participant is an employee of Insulet, an Investigator or Investigator's study team, or immediate family member (spouse, biological or legal guardian, child, sibling, parent) of any of the aforementioned
Inclusion Criteria
Inclusion Criteria:
1. Age at time of consent 18-75 years
2. Diagnosed with type 2 diabetes, on current insulin regimen for at least 3 months prior to screening (i.e. Basal-bolus, basal only or pre-mix)
3. Basal bolus (long-acting insulin and rapid acting analog) or pre-mix users with A1C \<12.0% OR basal users on long or intermediate acting insulin only with A1C \> 7.0% and \< 12.0%
4. Willing to use only the following types of U-100 insulin during the study: Humalog U-100, Novolog, or Admelog
5. Participant agrees to provide their own insulin for the duration of the study
6. Stable doses over the preceding 4 weeks of other glucose-lowering medications as determined by Investigator
7. Stable doses of weight loss medications over the preceding 4 weeks and throughout the study that may affect glycemic control directly and/or indirectly, except for a dose reduction or discontinuation, as determined by Investigator
8. Willing to wear the system continuously throughout the study
9. Deemed appropriate for pump therapy per investigator's assessment considering previous history of severe hypoglycemic and hyperglycemic events, and other comorbidities
10. Investigator has confidence that the participant has the cognitive ability and can successfully operate all study devices and can adhere to the protocol
11. Able to read and understand English or Spanish
12. Willing and able to sign the Informed Consent Form (ICF)
13. If female of childbearing potential, willing and able to have pregnancy testing
1. Age at time of consent 18-75 years
2. Diagnosed with type 2 diabetes, on current insulin regimen for at least 3 months prior to screening (i.e. Basal-bolus, basal only or pre-mix)
3. Basal bolus (long-acting insulin and rapid acting analog) or pre-mix users with A1C \<12.0% OR basal users on long or intermediate acting insulin only with A1C \> 7.0% and \< 12.0%
4. Willing to use only the following types of U-100 insulin during the study: Humalog U-100, Novolog, or Admelog
5. Participant agrees to provide their own insulin for the duration of the study
6. Stable doses over the preceding 4 weeks of other glucose-lowering medications as determined by Investigator
7. Stable doses of weight loss medications over the preceding 4 weeks and throughout the study that may affect glycemic control directly and/or indirectly, except for a dose reduction or discontinuation, as determined by Investigator
8. Willing to wear the system continuously throughout the study
9. Deemed appropriate for pump therapy per investigator's assessment considering previous history of severe hypoglycemic and hyperglycemic events, and other comorbidities
10. Investigator has confidence that the participant has the cognitive ability and can successfully operate all study devices and can adhere to the protocol
11. Able to read and understand English or Spanish
12. Willing and able to sign the Informed Consent Form (ICF)
13. If female of childbearing potential, willing and able to have pregnancy testing
Gender
All
Gender Based
false
Keywords
T2D
Omnipod
Automated Insulin Delivery
Healthy Volunteers
No
Last Update Post Date
Last Update Post Date Type
Actual
Last Update Submit Date
Maximum Age
75 Years
Minimum Age
18 Years
NCT Id
NCT05815342
Org Class
Industry
Org Full Name
Insulet Corporation
Org Study Id
G230013
Overall Status
Completed
Phases
Not Applicable
Primary Completion Date
Primary Completion Date Type
Actual
Official Title
Safety and Efficacy of the Omnipod 5 Automated Insulin Delivery System in Adults With Type 2 Diabetes
Primary Outcomes
Outcome Description
The change in HbA1c at 13 weeks from baseline
Outcome Measure
Change in HbA1c
Outcome Time Frame
Comparing the change in HbA1c during the 13 weeks study phase
Secondary Outcomes
Outcome Description
Glucose metric from study provided continuous glucose monitor (CGM)
Outcome Time Frame
Measuring mean glucose during the 13 weeks study phase
Outcome Measure
Mean Glucose
Outcome Description
Glucose metric from CGM
Outcome Time Frame
Measured during 13 weeks study phase
Outcome Measure
Percentage of time in range 70-180 mg/dL
Outcome Description
Glucose metric from study CGM
Outcome Time Frame
Measured during 13 weeks study phase
Outcome Measure
Percent of Time in Range 70-140 mg/dL
Outcome Description
Glucose metric from CGM
Outcome Time Frame
Measured during 13 weeks study phase
Outcome Measure
Percent of Time ≥ 300 mg/dL
Outcome Description
Glucose metric from CGM
Outcome Time Frame
Measured during 13 weeks study phase
Outcome Measure
Percent of Time > 250 mg/dL
Outcome Description
Glucose metric from CGM
Outcome Time Frame
Measured during 13 weeks study phase
Outcome Measure
Percent of Time >180 mg/dL
Outcome Description
Glucose metric from CGM
Outcome Time Frame
Measured during 13 weeks study phase
Outcome Measure
Percent of Time < 70 mg/dL
Outcome Description
Glucose metric from CGM
Outcome Time Frame
Measured during 13 weeks study phase
Outcome Measure
Percent of Time < 54 mg/dL
Outcome Description
A questionnaire that measures seven critical dimensions of distress (28-item scale with 6 choices that range from 1 (Not a Problem) to 6 (A Very Serious Problem)). The total score can range from 1 to 6, with a lower score indicating a better outcome.
Outcome Time Frame
Baseline compared to end of week 13 visit
Outcome Measure
Change from baseline in T2-DDAS total score
Outcome Description
A questionnaire that measures seven critical dimensions of distress (28-item scale with 6 choices that range from 1 (Not a Problem) to 6 (A Very Serious Problem)). The total score can range from 1 to 6, with a lower score indicating a better outcome.
Outcome Time Frame
Baseline compared to end week 13 visit
Outcome Measure
% Meeting MCID for T2-DDAS
Outcome Description
Change from baseline in PSQI total score which assesses sleep quality over a one month interval. The survey includes 10 self-rated items.
Outcome Time Frame
Baseline compared to end of week 13 visit
Outcome Measure
Change from baseline in Pittsburgh Sleep Quality Index total score
Outcome Description
Change from baseline in PSQI total score which assesses sleep quality over a one month interval. The survey includes 10 self-rated items.
Outcome Time Frame
Baseline compared to end of week 13 visit
Outcome Measure
% Meeting MCID for Pittsburgh Sleep Quality Index
Outcome Description
Questionnaire that examines the degree to which people with diabetes feel able, secure, and comfortable regarding their ability to stay safe from hypoglycemic-related problems (9-item scale with 4 choices that range from 1 (Not Confident At All) to 4 (Very Confident)). The total score can range from 1 to 4, with a higher score indicating a better outcome.
Outcome Time Frame
Baseline compared to end week 13 visit
Outcome Measure
Change from baseline in HCS total score
Outcome Description
Questionnaire that examines the degree to which people with diabetes feel able, secure, and comfortable regarding their ability to stay safe from hypoglycemic-related problems (9-item scale with 4 choices that range from 1 (Not Confident At All) to 4 (Very Confident)). The total score can range from 1 to 4, with a higher score indicating a better outcome.
Outcome Time Frame
Baseline compared to end week 13 visit
Outcome Measure
% Meeting MCID for HCS
Outcome Description
Glucose metric from CGM
Outcome Time Frame
Measured during 13 weeks study phase
Outcome Measure
Percentage of time <70 mg/dL
Outcome Description
Glucose metric from CGM
Outcome Time Frame
Measured during 13 weeks study phase
Outcome Measure
Percentage of time <54 mg/dL
Outcome Description
Glucose metric from CGM measured glucose variability with the coefficient of variation (CV)
Outcome Time Frame
Measured during 13 weeks study phase and compared to standard therapy
Outcome Measure
Coefficient of variation
Start Date
Start Date Type
Actual
Status Verified Date
First Post Date
First Post Date Type
Actual
First Submit Date
First Submit QC Date
Std Ages
Adult
Older Adult
Maximum Age Number (converted to Years and rounded down)
75
Minimum Age Number (converted to Years and rounded down)
18
Investigators
Investigator Type
Principal Investigator
Investigator Name
Shivani Agarwal
Investigator Email
shivani.agarwal@einsteinmed.org
Investigator Phone
9175766590